

PCT REQUEST

Original (for SUBMISSION) - printed on 02.07.2003 11:20:44 AM

0	For receiving Office use only International Application No.	
0-1		
0-2	International Filing Date	
0-3	Name of receiving Office and "PCT International Application"	
0-4	Form - PCT/RO/101 PCT Request	
0-4-1	Prepared using PCT-EASY Version 2.92 (updated 01.04.2003)	
0-5	Petition The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	Receiving Office (specified by the applicant) Danish Patent and Trademark Office (RO/DK)	
0-7	Applicant's or agent's file reference 022-2003 WO1	
I	Title of invention METHOD FOR TREATING DIABETES AND RELATED DISORDERS	
II	Applicant This person is: Applicant for Name Address:	
II-1	applicant only	
II-2	all designated States except US	
II-4	ZEALAND PHARMA A/S	
II-5	Smedeland 26B DK-2600 Glostrup Denmark	
II-6	State of nationality DK	
II-7	State of residence DK	
II-8	Telephone No. +45 43 28 12 00	
II-9	Facsimile No. +45 43 28 12 12	
II-10	e-mail lsd@zp.dk	
III-1	Applicant and/or inventor This person is: Applicant for Name (LAST, First) Address:	
III-1-1	applicant and inventor	
III-1-2	US only	
III-1-4	STEINESS, Eva	
III-1-5	Sømarksvej 11 DK-2900 Hellerup Denmark	
III-1-6	State of nationality DK	
III-1-7	State of residence DK	

BEST AVAILABLE COPY

PCT REQUEST

2/4


022-2003 WO1

Original (for SUBMISSION) - printed on 02.07.2003 11:20:44 AM

V	Designation of States	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	<p>AP: GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT</p> <p>EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT</p> <p>EP: AT BE BG CH&LI CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR and any other State which is a Contracting State of the European Patent Convention and of the PCT</p> <p>OA: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT</p>
V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	<p>AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH&LI CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW</p>
V-5	Precautionary Designation Statement In addition to the designations made under items V-1, V-2 and V-3, the applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.	
V-6	Exclusion(s) from precautionary designations	NONE
VI-1	Priority claim of earlier national application	
VI-1-1	Filing date	04 July 2002 (04.07.2002)
VI-1-2	Number	60/393,917
VI-1-3	Country	US

PCT REQUEST

Original (for SUBMISSION) - printed on 02.07.2003 11:20:44 AM

VI-2	Priority claim of earlier national application		
VI-2-1	Filing date	24 April 2003 (24.04.2003)	
VI-2-2	Number	60/465,613	
VI-2-3	Country	US	
VII-1	International Searching Authority Chosen	European Patent Office (EPO) (ISA/EP)	
VIII	Declarations	Number of declarations	
VIII-1	Declaration as to the identity of the inventor	-	
VIII-2	Declaration as to the applicant's entitlement, as at the international filing date, to apply for and be granted a patent	-	
VIII-3	Declaration as to the applicant's entitlement, as at the international filing date, to claim the priority of the earlier application	-	
VIII-4	Declaration of inventorship (only for the purposes of the designation of the United States of America)	-	
VIII-5	Declaration as to non-prejudicial disclosures or exceptions to lack of novelty	-	
IX	Check list	number of sheets	electronic file(s) attached
IX-1	Request (including declaration sheets)	4	-
IX-2	Description	43	-
IX-3	Claims	10	-
IX-4	Abstract	1	EZABST00.TXT
IX-5	Drawings	8	-
IX-7	TOTAL	66	
IX-19	Accompanying Items	paper document(s) attached	electronic file(s) attached
IX-8	Fee calculation sheet	✓	-
IX-17	PCT-EASY diskette	-	Diskette
IX-19	Figure of the drawings which should accompany the abstract		
IX-20	Language of filing of the international application	English	
X-1	Signature of applicant, agent or common representative		
X-1-1	Name	ZEALAND PHARMA A/S	
X-1-2	Name of signatory	Maj Hilligesøe	
X-1-3	Capacity	Patent Manager	
X-2	Signature of applicant, agent or common representative		
X-2-1	Name (LAST, First)	STEINESS, Eva	

FOR RECEIVING OFFICE USE ONLY

10-1	Date of actual receipt of the purported international application	
------	---	--

PCT REQUEST

Original (for SUBMISSION) - printed on 02.07.2003 11:20:44 AM

10-2	Drawings:	
10-2-1	Received	
10-2-2	Not received	
10-3	Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application	
10-4	Date of timely receipt of the required corrections under PCT Article 11(2)	
10-5	International Searching Authority	ISA/EP
10-6	Transmittal of search copy delayed until search fee is paid	

FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau	
------	--	--

PCT (ANNEX - FEE CALCULATION SHEET)

Original (for SUBMISSION) - printed on 02.07.2003 11:20:44 AM

022-2003 WO1

(This sheet is not part of and does not count as a sheet of the international application)

0	For receiving Office use only		
0-1	International Application No.		
0-2	Date stamp of the receiving Office		
0-4	Form - PCT/RO/101 (Annex) PCT Fee Calculation Sheet		
0-4-1	Prepared using	PCT-EASY Version 2.92 (updated 01.04.2003)	
0-9	Applicant's or agent's file reference	022-2003 WO1	
2	Applicant	ZEALAND PHARMA A/S, et al.	
12	Calculation of prescribed fees	fee amount/multiplier	Total amounts (DKK)
12-1	Transmittal fee T	⇒	1,500
12-2-1	Search fee S	⇒	7,030
12-2-2	International search to be carried out by EP		
12-3	International fee		
	Basic fee (first 30 sheets) b1	3,300	
12-4	Remaining sheets 36		
12-5	Additional amount (X) 80		
12-6	Total additional amount b2 2,880		
12-7	b1 + b2 = B 6,180		
12-8	Designation fees		
	Number of designations contained in international application 97		
12-9	Number of designation fees payable (maximum 5) 5		
12-10	Amount of designation fee (X) 710		
12-11	Total designation fees D 3,550		
12-12	PCT-EASY fee reduction R -1,020		
12-13	Total International fee (B+D-R) I 8,710		
12-17	TOTAL FEES PAYABLE (T+S+I+P) ⇒ 17,240		
12-19	Mode of payment cheque		

VALIDATION LOG AND REMARKS

13-2-7	Validation messages Contents	Green? Figure of the drawings which should accompany the abstract not specified. Please verify.
		Green? Priority 1. The priority document is not enclosed. (The applicant must furnish it within 16 months from the earliest priority date claimed)

PCT (ANNEX - FEE CALCULATION SHEET)

Original (for SUBMISSION) - printed on 02.07.2003 11:20:44 AM

022-2003 WO1

	Green? Priority 2. The priority document is not enclosed. (The applicant must furnish it within 16 months from the earliest priority date claimed)
13-2-8	Validation messages Fees Green? Please confirm that fee schedule utilized is the latest available

Abstract

The present invention relates to use of GLP-1 or a related molecule having GLP-effect for the manufacture of a medicament for preventing or treating diabetes in a mammal. The amount and timing of administration of said medicament are subsequently reduced to produce a "drug holiday". Practice of the invention achieves effective therapy without continuous drug exposure and without continuous presence of therapeutic levels of the drug. The invention also discloses a method of treating diabetes and related disorders in a mammal by administering glucagon like peptide (GLP-1) or a related molecule having GLP-1 like effect and thereby providing a therapeutically effective amount of endogenous insulin.

Original (for SUBMISSION) - printed on 02.07.2003 11:20:44 AM

PCT-EASY INFORMATION SHEET
(For applicant use only, DO NOT submit this sheet with the international application)

VALIDATION LOG

Green?	Contents Figure of the drawings which should accompany the abstract not specified. Please verify.
Green?	Priority 1. The priority document is not enclosed. (The applicant must furnish it within 16 months from the earliest priority date claimed)
Green?	Priority 2. The priority document is not enclosed. (The applicant must furnish it within 16 months from the earliest priority date claimed)
Green?	Fees Please confirm that fee schedule utilized is the latest available

Before submitting the International Application, please carefully verify that:

- the information contained on printed Request form is correct;
- Box X of the Request form has been signed;
- all elements of the international application as indicated in Boxes VIII and IX of the Request form have been attached; and,
- the diskette containing the PCT-EASY zip file of the International Application has been enclosed and has been clearly labeled "PCT-EASY", with the applicant's or agent's file reference, and the first applicant's name.

ATTENTION

DO NOT modify any indications on the Request form printout. The electronic version of the PCT-EASY application has been locked. If an error or an omission is discovered at this time, you must reopen the stored form for submission, perform necessary amendments and immediately resubmit the form. Finally, a NEW submission diskette must be created manually by resending the corrected stored form to the diskette. The previously created printout and submission diskette must be destroyed in order to prevent the possibility of erroneously sending it to the RO.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

BLACK BORDERS

IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT OR DRAWING

BLURRED OR ILLEGIBLE TEXT OR DRAWING

SKEWED/SLANTED IMAGES

COLOR OR BLACK AND WHITE PHOTOGRAPHS

GRAY SCALE DOCUMENTS

LINES OR MARKS ON ORIGINAL DOCUMENT

REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.